The Role of Epigenetics in Mitochondrial Biogenesis-Mediated Recovery after Spinal Cord Injury
The Role of Epigenetics in Mitochondrial Biogenesis-Mediated Recovery after Spinal Cord Injury
批准号:
10216171
负责人:
Natalie E Scholpa
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-08-01 至 2025-07-31
关键词:
ADRB2 geneAddressAdrenergic AgonistsAffectAgeAgonistAntioxidantsAreaBehavioralBiogenesisBioinformaticsBiologyBlood VesselsCaringCell physiologyClinicalClinical TrialsCommunicationComplexDataDevelopmentDevelopment PlansDevicesDiseaseDoctor of PhilosophyEpigenetic ProcessEventExposure toFDA approvedFemaleFinancial compensationFunctional disorderGene Expression ProfilingGenesGeneticGenetic TranscriptionGenomicsGoalsHealth Care CostsHealthcareHealthcare SystemsHumanIndividualInjuryIntensive CareInvestigationKnowledgeLaboratoriesLesionLocomotor RecoveryMaintenanceMediatingMediator of activation proteinMedicalMentorsMitochondriaModificationMolecularMusNatureNeurosurgeonOralOxygenPathologyPatientsPharmacologyPhasePlayPublishingRecoveryRehabilitation therapyReportingResearch PersonnelRoleSiteSpinal CordSpinal cord injuryTherapeuticTimeTrainingTraumaUnited StatesUnited States Department of Veterans AffairsVeteransbeta-2 Adrenergic Receptorscareercareer developmentclinical applicationcostdisabilityeducational atmosphereepigenomeexperienceformoterolimprovedin vivoinjury recoveryinnovationloss of functionmalemitochondrial dysfunctionnovel strategiespreventservice memberskillstherapeutic targettreatment group
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The goal of this project is to determine the role of epigenetic modifications of mitochondrial genes in
the induction of the plateau phase after spinal cord injury (SCI), and to exploit these modifications to
promote recovery. SCI is a devastating disorder often resulting in loss of function below the injury site. In recent
years, service members have been threatened by more advanced warfare, such as improvised explosive
devices, ultimately inducing more severe and complex injuries, including SCI. The devastating and debilitating
nature of these injuries has not been lessened. The Department of Veterans Affairs (VA) is the largest healthcare
network for individuals suffering from SCI, providing care for 25% of total victims in the United States. Improved
therapeutics for the treatment of SCI would greatly benefit not only sufferers, but also the VA healthcare system.
SCI is defined by direct trauma to the spinal cord, which disrupts the vasculature, leading to decreased oxygen
delivery within the area and reducing the ability of mitochondria to maintain cellular energetics. Thus far, the
majority of studies targeting mitochondrial dysfunction following SCI have focused on downstream aspects of
mitochondrial function (e.g. antioxidant defenses). Reestablishment of mitochondrial function through
pharmacological induction of mitochondrial biogenesis (MB) remains an underexplored but novel strategy.
I previously reported that treatment with the mitochondrially biogenic FDA-approved β2-adrenergic receptor
agonist formoterol beginning up to 8h after SCI improves spinal cord mitochondrial function, decreases lesion
volume and enhances locomotor recovery by 7 days post-injury (DPI). Consistent with other published data, the
majority of the improvements observed with formoterol occurred within the first 2 weeks, after which recovery
plateaued. A similar effect is observed in humans, with the majority of recovery taking place within the first year
then reaching a plateau. The mechanism behind the development of this plateau phase, however, is not fully
understood. By determining the mechanism of its formation, the plateau phase could be prevented and/or
reversed, potentially allowing for continued recovery following injury. My preliminary studies revealed genetic
differences within the injured spinal cord of formoterol-treated mice between the recovery phase (7 DPI) and the
plateau phase (15 DPI), namely a decrease in genes associated with mitochondrial function, and a concurrent
increase in genes associated with epigenetic modifications. Therefore, I hypothesize that epigenetic
alterations contribute to decreased transcription of mitochondrial genes within the spinal cord during
the plateau phase, preventing continued recovery of mitochondrial function and limiting the efficacy of
formoterol treatment in mice. To address this hypothesis, I propose the following Specific Aims: 1) Further
elucidate the genetic profile within the spinal cord during the post-SCI recovery period (7 DPI) and plateau phase
(≥15 DPI), with and without formoterol treatment in mice; 2) Elucidate the mechanisms of epigenetic
modifications on the transcription of mitochondrial genes during the transition from recovery to plateau phase
post-SCI, with and without formoterol treatment; 3) Assess the pharmacological efficacy of inhibiting epigenetic
events on MB and recovery post-SCI in vivo, with and without formoterol treatment.
Successful completion of this proposal could provide integral information into the recovery plateau observed
after SCI. I am using an FDA-approved compound, male and female mice and initiating treatment up to 8h after
injury, emphasizing the clinical applicability. This proposal will also directly assess the therapeutic potential of
my findings by determining if modulation of epigenetic status improves recovery after injury.
My mentoring team has formulated a comprehensive career development plan that includes exposure to a rich
educational environment, opportunities to improve oral and written communication skills and mentoring on
project and laboratory maintenance to ease transition to independence. This project and training will facilitate
the completion of my long-term career goal of becoming and independent VA researcher.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of Epigenetics in Mitochondrial Biogenesis-Mediated Recovery after Spinal Cord Injury
-
批准号:10477196
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Natalie E Scholpa
-
依托单位:
The Role of Epigenetics in Mitochondrial Biogenesis-Mediated Recovery after Spinal Cord Injury
-
批准号:10013655
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Natalie E Scholpa
-
依托单位:
海外基金